‘EL LOTO AZUL’ · ED. FACSIMIL EN B/N COLOREADA · EN FRANCÉS
‘EL LOTO AZUL’ · ED. FACSIMIL EN B/N COLOREADA · EN FRANCÉS
Related Articles
Conversations on Cancer – Pediatric Cancers: Navigating the Challenges Together
Take this survey powered by surveymonkey.com. Create your own surveys for free.
213 CNOS to know | 2024
Becker’s is thrilled to honor healthcare CNOs. Chief nursing officers are responsible for tackling nurse staffing shortages, managing nursing budgets and more.
Mutant KRAS in Circulating Tumor DNA as a Biomarker in… : Annals of Surgery
round Data: Increasingly, ctDNA is being used for clinical decision-making in a variety of solid malignancies. However, the detection and prognostic value of KRAS ctDNA…
Genetic Risk Score Offers Insight Into CLL Predisposition
Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.
Evolving Paradigms In Advanced Ovarian Cancer Care | Optimizing Physician and Patient Conversations by Understanding Perspectives
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated (g BRCA m or s BRCA m) advanced…
Philip Abbosh on a Urine Biopsy for Bladder Cancer Staging
A next-generation sequencing–based molecular assay using urine holds promise for improving the clinical staging of non-metastatic muscle-invasive bladder cancer (MIBC). The assay, the Noninvasive Test…
Mirdametinib May Provide Long-Awaited Treatment Alternative for Adults/Children With NF1-PNs
Angela Hirbe, MD, PhD, discusses the potential significance of MET inhibitors such as mirdametinib for adult and pediatric patients with NF1-PN.
61 Insights into interferons (IFN)-myeloid cell crosstalk: an analysis of E3611 testing ipilimumab alone or in combination with IFN-α in advanced melanoma
Background IFNs could reprogram immunosuppressive myelopoiesis, induce accumulation of APCs with capacity to prime anti-tumor immunity. IFN-α favors a Th1 shift in immunity and concurrent…
